Kalaris Therapeutics (NASDAQ:KLRS) Rating Increased to Strong-Buy at Wedbush

Wedbush upgraded shares of Kalaris Therapeutics (NASDAQ:KLRS) to a strong-buy rating in a report published on Thursday,Zacks.com reports.

KLRS has been the topic of several other research reports. Morgan Stanley began coverage on Kalaris Therapeutics in a research note on Thursday, April 16th. They set an “overweight” rating and a $14.00 price objective on the stock. Wall Street Zen raised Kalaris Therapeutics from a “sell” rating to a “hold” rating in a research note on Sunday, March 15th. Citigroup restated an “outperform” rating on shares of Kalaris Therapeutics in a report on Wednesday. Finally, Citizens Jmp dropped their price target on Kalaris Therapeutics from $26.00 to $25.00 and set a “market outperform” rating on the stock in a research report on Wednesday. Two investment analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Kalaris Therapeutics presently has an average rating of “Moderate Buy” and an average price target of $15.60.

Kalaris Therapeutics Price Performance

Kalaris Therapeutics stock opened at $5.22 on Thursday. The firm has a market capitalization of $120.02 million, a price-to-earnings ratio of -2.43 and a beta of 0.15. The company’s 50 day simple moving average is $6.58 and its 200 day simple moving average is $7.52. Kalaris Therapeutics has a fifty-two week low of $2.14 and a fifty-two week high of $11.88.

Kalaris Therapeutics (NASDAQ:KLRS) last posted its earnings results on Tuesday, May 12th. The company reported ($0.46) earnings per share for the quarter, topping the consensus estimate of ($0.52) by $0.06. As a group, analysts predict that Kalaris Therapeutics will post -2.15 EPS for the current fiscal year.

Institutional Investors Weigh In On Kalaris Therapeutics

Several institutional investors have recently added to or reduced their stakes in KLRS. XTX Topco Ltd acquired a new position in Kalaris Therapeutics in the 2nd quarter worth $65,000. Fortis Capital Advisors LLC bought a new position in Kalaris Therapeutics during the 3rd quarter worth about $231,000. Belpointe Asset Management LLC acquired a new stake in shares of Kalaris Therapeutics in the 3rd quarter valued at about $231,000. Johnson Financial Group Inc. acquired a new stake in shares of Kalaris Therapeutics in the 3rd quarter valued at about $58,000. Finally, Bridgeway Capital Management LLC bought a new stake in shares of Kalaris Therapeutics in the third quarter valued at about $130,000. 66.05% of the stock is owned by institutional investors.

About Kalaris Therapeutics

Allovir, Inc, a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company’s lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus. Its preclinical and clinical development product candidates include ALVR106 for the respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109 to treat SARS-CoV-2 and COVID-19; ALVR107 for treating hepatitis B; and ALVR108.